Why Teva Pharmaceutical Stock Rocked the Market Today

Core Insights - Teva Pharmaceutical Industries experienced a significant stock price increase of nearly 21% following a strong quarterly earnings report, outperforming the S&P 500 index's 0.4% rise [1] Financial Performance - In Q3, Teva reported revenue of $4.48 billion, marking a 3% year-over-year increase, driven by strong sales of key medications such as Austedo, which saw a 38% increase to $618 million, and Ajovy, which rose 19% to $168 million [2] - Teva's non-GAAP net income rose by 14% to $910 million, equating to $0.78 per share, surpassing analyst expectations of $4.36 billion in revenue and $0.68 per share for non-GAAP net profit [3] Guidance Adjustments - Teva revised its full-year 2025 revenue guidance, lowering the upper end by $200 million to a range of $16.8 billion to $17 billion, while maintaining its net income forecast at $2.55 to $2.65 per share for the year [4]